Donor- and transplant-related characteristics of nonmanipulated unrelated bone marrow (UBMT), T-cell–depleted unrelated bone marrow transplants (T-UBMT), and umbilical unrelated cord blood recipients (UCBT)
| Characteristics . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . | P value3-150 . |
|---|---|---|---|---|
| Donor-related | ||||
| Gender match | 125 (48%) | 96 (53%) | 49 (49%) | .51 |
| Male donor to female recipient | 56 (21%) | 38 (21%) | 19 (19%) | .25 |
| Male donor to male recipient | 78 (30%) | 72 (40%) | 28 (28,5%) | |
| Female donor to male recipient | 80 (31%) | 46 (26%) | 28 (28,5%) | |
| Female donor to female recipient | 47 (18%) | 24 (13%) | 21 (21%) | |
| Missing data | 1 (0.4%) | 0 | 3 (4%) | |
| ABO compatible | 110 (42%) | 81 (45%) | 41 (41%) | .78 |
| Missing data | 1 (0.4%) | 3 (1.6%) | 0 | |
| ABO major incompatible | 89 (34%) | 53 (29%) | 36 (36%) | .44 |
| HLA disparities3-151 | ||||
| 0 | 211 (80.5%) | 97 (54%) | 8 (8%) | .0001 |
| 1 | 46 (17.6%) | 61 (34%) | 43 (43%) | |
| 2 | 1 (0.4%) | 10 (5.5%) | 40 (41%) | |
| 3 | — | 2 (1%) | 6 (6%) | |
| 4 | — | 1 (1%) | ||
| Missing data | 4 (1.5%) | 10 (5.5%) | 1 (1%) | |
| Donor positive CMV serology | 112 (43%) | 73 (41%) | 0 | .0001 |
| Donor's age | 36 (28-42) | 37 (31-43) | — | .103-152 |
| Missing data | 26 (10%) | 5 (3%) | ||
| Transplant-related | ||||
| Graft before January 1, 1996 | 107 (41%) | 85 (47%) | 10 (10%) | .0001 |
| Conditioning regimen | ||||
| BUCY | 12 (5%) | 6 (3%) | 13 (13%) | .002 |
| TBI + CY | 103 (39%) | 122 (68%) | 17 (17%) | .0001 |
| TBI + 2 or more drugs | 109 (42%) | 36 (20%) | 35 (35%) | .0001 |
| Anti-T cell antibodies | ||||
| No | 97 (37%) | 14 (8%) | 12 (12%) | .0001 |
| ALG/ATG | 130 (50%) | 44 (24%) | 82 (84%) | |
| Monoclonal antibody | 34 (13%) | 122 (68%) | 4 (4%) | |
| GVHD prophylaxis | ||||
| No | 0 | 2 | 0 | |
| CsA alone | 8 (3%) | 94 (52%) | 7 (7%) | |
| CsA + pred | 2 (0,8%) | 9 (5%) | 62 (63%) | .0001 |
| CsA + MTX | 180 (69%) | 53 (30%) | 9 (9%) | |
| CsA + MTX + pred ± ATG/ALG | 36 (14%) | 8 (4%) | 9 (9%) | |
| CsA + ATG/ALG ± pred | 4 (2%) | 9 (5%) | 6 (6%) | |
| Others | 32 (12%) | 5 (3%) | 6 (6%) | |
| T depletion (methods) | — | 180 | — | — |
| Campath | 132 (73%) | |||
| Elutriation | 12 (7%) | |||
| E-rosetting | 11 (6%) | |||
| CD34 positive selection | 16 (9%) | |||
| Others | 9 (5%) | |||
| Early growth factors (< day 8) | 96 (37%) | 42 (23%) | 54 (55%) | .0001 |
| Nucleated cells infused/kg (108) | 4.2 (3.0-6.0) | 3.8 (1.4-5.6) | 0.38 (0.24-3.6) | .0001 |
| Missing data | 8 (3%) | 11 (6%) | 6 (6%) | |
| Median follow up time, months | 30 (17-43) | 33 (18-47) | 19 (13-29) | .0001 |
| Lost to follow-up at 01/01/99 | 0 | 9 (5%) | 0 | .0001 |
| Characteristics . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . | P value3-150 . |
|---|---|---|---|---|
| Donor-related | ||||
| Gender match | 125 (48%) | 96 (53%) | 49 (49%) | .51 |
| Male donor to female recipient | 56 (21%) | 38 (21%) | 19 (19%) | .25 |
| Male donor to male recipient | 78 (30%) | 72 (40%) | 28 (28,5%) | |
| Female donor to male recipient | 80 (31%) | 46 (26%) | 28 (28,5%) | |
| Female donor to female recipient | 47 (18%) | 24 (13%) | 21 (21%) | |
| Missing data | 1 (0.4%) | 0 | 3 (4%) | |
| ABO compatible | 110 (42%) | 81 (45%) | 41 (41%) | .78 |
| Missing data | 1 (0.4%) | 3 (1.6%) | 0 | |
| ABO major incompatible | 89 (34%) | 53 (29%) | 36 (36%) | .44 |
| HLA disparities3-151 | ||||
| 0 | 211 (80.5%) | 97 (54%) | 8 (8%) | .0001 |
| 1 | 46 (17.6%) | 61 (34%) | 43 (43%) | |
| 2 | 1 (0.4%) | 10 (5.5%) | 40 (41%) | |
| 3 | — | 2 (1%) | 6 (6%) | |
| 4 | — | 1 (1%) | ||
| Missing data | 4 (1.5%) | 10 (5.5%) | 1 (1%) | |
| Donor positive CMV serology | 112 (43%) | 73 (41%) | 0 | .0001 |
| Donor's age | 36 (28-42) | 37 (31-43) | — | .103-152 |
| Missing data | 26 (10%) | 5 (3%) | ||
| Transplant-related | ||||
| Graft before January 1, 1996 | 107 (41%) | 85 (47%) | 10 (10%) | .0001 |
| Conditioning regimen | ||||
| BUCY | 12 (5%) | 6 (3%) | 13 (13%) | .002 |
| TBI + CY | 103 (39%) | 122 (68%) | 17 (17%) | .0001 |
| TBI + 2 or more drugs | 109 (42%) | 36 (20%) | 35 (35%) | .0001 |
| Anti-T cell antibodies | ||||
| No | 97 (37%) | 14 (8%) | 12 (12%) | .0001 |
| ALG/ATG | 130 (50%) | 44 (24%) | 82 (84%) | |
| Monoclonal antibody | 34 (13%) | 122 (68%) | 4 (4%) | |
| GVHD prophylaxis | ||||
| No | 0 | 2 | 0 | |
| CsA alone | 8 (3%) | 94 (52%) | 7 (7%) | |
| CsA + pred | 2 (0,8%) | 9 (5%) | 62 (63%) | .0001 |
| CsA + MTX | 180 (69%) | 53 (30%) | 9 (9%) | |
| CsA + MTX + pred ± ATG/ALG | 36 (14%) | 8 (4%) | 9 (9%) | |
| CsA + ATG/ALG ± pred | 4 (2%) | 9 (5%) | 6 (6%) | |
| Others | 32 (12%) | 5 (3%) | 6 (6%) | |
| T depletion (methods) | — | 180 | — | — |
| Campath | 132 (73%) | |||
| Elutriation | 12 (7%) | |||
| E-rosetting | 11 (6%) | |||
| CD34 positive selection | 16 (9%) | |||
| Others | 9 (5%) | |||
| Early growth factors (< day 8) | 96 (37%) | 42 (23%) | 54 (55%) | .0001 |
| Nucleated cells infused/kg (108) | 4.2 (3.0-6.0) | 3.8 (1.4-5.6) | 0.38 (0.24-3.6) | .0001 |
| Missing data | 8 (3%) | 11 (6%) | 6 (6%) | |
| Median follow up time, months | 30 (17-43) | 33 (18-47) | 19 (13-29) | .0001 |
| Lost to follow-up at 01/01/99 | 0 | 9 (5%) | 0 | .0001 |
P value: Fisher test for categoric variables and Kruskal-Wallis for continuous variables. For continuous variables, medians (25th-75th percentiles) are given; for qualitative variables, sample sizes (percentages) are given within each strata.
A and B by serology and allelic typing for DRB1.
P value corresponds to the comparison between UBMT and T-UBMT since the age of UCBT is nonsensical.
CMV indicates human cytomegalovirus; BU, busulfan; CY, cyclophosphamide; TBI, total body irradiation; ALG, antilymphocyte globulin; ATG, antihymocyte globulin; CsA, ciclosporine A; MTX, methotrexate; Pred, prednisone.